1. Was DNA Microarrays a sensible growth opportunity for Corning to
pursue?
2. What are the differences between the CMT business model and the general
business model for Corning Technologies?
3. Did Corning build an adequate level of expertise in molecular biology?
Explain.
4. Why did the initial microarray leadership team falter?
5. Evaluate Greg Brown’s priorities upon taking over the newly created CMT
division.
6. How was the microarray venture affected by the buildup and subsequent
sudden decline of the telecommunications business?
7. On a graph over time, trace perceptions of how the microarray venture was
performing. On what basis did these perceptions form? Change? Evaluate.
8. In 2002, how secure do you suspect was Affymetrix position in the
microarray market? Explain.
6. If so, how would the change you propose affect:
a. NYTD’s culture and leadership style?
b. NYTD’s likely budget?
c. The way NYTD’s performance is judged?
d. The way new ideas for the websites are generated?